Phase II trial of sorafenib in metastatic thyroid cancer (Q37158278)

18 August 2017

Phase II trial of sorafenib in metastatic thyroid cancer (English)

1 reference

18 August 2017

phase II clinical trial

0 references

1 reference

Richard T Kloos

1

1 reference

18 August 2017

Matthew D Ringel

2

1 reference

18 August 2017

Michael V Knopp

3

1 reference

18 August 2017

Nathan C Hall

4

1 reference

18 August 2017

Mark King

5

1 reference

18 August 2017

Robert Stevens

6

1 reference

18 August 2017

Jiachao Liang

7

1 reference

18 August 2017

Paul E Wakely

8

1 reference

18 August 2017

Vasyl V Vasko

9

1 reference

18 August 2017

Motoyasu Saji

10

1 reference

18 August 2017

Jennifer Rittenberry

11

1 reference

18 August 2017

Lai Wei

12

1 reference

18 August 2017

Daria Arbogast

13

1 reference

18 August 2017

Minden Collamore

14

1 reference

18 August 2017

John J Wright

15

1 reference

18 August 2017

Michael Grever

16

1 reference

18 August 2017

Manisha H Shah

17

1 reference

18 August 2017

language of work or name

English

0 references

publication date

2 March 2009

1 reference

Journal of Clinical Oncology

18 August 2017

1 reference

18 August 2017

27

1 reference

18 August 2017

10

1 reference

18 August 2017

1675-1684

1 reference

Motesanib diphosphate in progressive differentiated thyroid cancer.

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668972

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668972

Phase II trial of sorafenib in advanced thyroid cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668972

Keratoacanthomas associated with sorafenib therapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668972

Vascular endothelial growth factor in thyroid cancers

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668972

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668972

BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668972

Angiogenesis in endocrine tumors.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668972

RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668972

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668972

Functional magnetic resonance imaging in oncology for diagnosis and therapy monitoring

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668972

The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668972

VEGF and the quest for tumour angiogenesis factors

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668972

MAP kinases and hypoxia in the control of VEGF expression

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668972

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668972

Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668972

Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668972

Regulation of FRTL-5 thyroid cell growth by phosphatidylinositol (OH) 3 kinase-dependent Akt-mediated signaling

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668972

p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668972

Optimal two-stage designs for phase II clinical trials

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668972

Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668972

BRAF is a therapeutic target in aggressive thyroid carcinoma.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668972

BRAF mutations in an Italian cohort of thyroid cancers.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668972

BRAF mutations in papillary carcinomas of the thyroid

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668972

High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668972

Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)?

3 September 2018

1 reference

12 December 2020

Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation

1 reference

12 December 2020

BRAF Mutation in Papillary Thyroid Carcinoma

1 reference

12 December 2020

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

1 reference

12 December 2020

Is there room for improvement in adverse event reporting in the era of targeted therapies?

1 reference

12 December 2020

BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC

1 reference

12 December 2020

BRAF mutations are associated with some histological types of papillary thyroid carcinoma

1 reference

12 December 2020

Identifiers

DOI

10.1200/JCO.2008.18.2717

1 reference

18 August 2017

1 reference

18 August 2017

1 reference